Iovance Biotherapeutics is a biopharmaceutical company that develops and markets cell-based treatments for solid tumors and blood cancers, primarily using patient-derived tumor-infiltrating lymphocytes. The company's approved therapies include Amtagvi for advanced melanoma and Proleukin for melanoma and renal cell carcinoma, while its pipeline encompasses multiple investigational candidates targeting melanoma, lung cancer, cervical cancer, endometrial cancer, and hematologic malignancies. The company maintains partnerships with government research institutions and pharmaceutical companies to support its development programs.

entry readiness 0 · NOT READY · exit proximity 90

Value area 3.32–5.21 · 0% of 120d volume overhead · clean runway